| Rx0000437 |
Genus Lifesciences Inc. |
03/31/2022 |
64950034245 |
Hydrocodone with Homatropine solution, 5mL UD, pack of 40 |
03/01/2022 |
84.85 |
390.00 |
None |
Innovator Multiple Source Drug |
600 |
None |
Increase in materials, labor and overhead costs |
None |
Continual evaluation of process improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000406 |
Glaukos Corporation |
03/31/2022 |
25357002503 |
Riboflavin 5’-phosphate in 20% dextran ophthalmic solution and riboflavin 5’-phosphate ophthalmic solution, 1.56 mg/mL Photrexa Viscous and 1.46 mg/mL Photrexa, single-use foil pouch, for topical administration |
01/01/2022 |
305.00 |
3435.00 |
None |
Single Source Drug |
None |
1 |
In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs. |
None |
No change or improvement in the drug product necessitated the price increase. |
None |
11/21/2019 |
Avedro, Inc. |
437751000 |
None |
Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction. |
2850.00 |
2850.00 |
2016 |
595.00 |
None |
None |
| Rx0000029 |
GlaxoSmithKline |
09/30/2022 |
49401008801 |
BENLYSTA; 200 mg/mL; 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01) |
07/01/2022 |
20.99 |
1070.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
09/30/2022 |
49401008842 |
BENLYSTA; 200 mg/mL; 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42) |
07/01/2022 |
20.99 |
1070.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
09/30/2022 |
49401008835 |
BENLYSTA; 200 mg/mL; 4 PREFILLED AUTO-INJECTOR in 1 CARTON (49401-0088-35) > 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01) |
07/01/2022 |
83.96 |
4282.17 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
09/30/2022 |
49401008847 |
BENLYSTA; 200 mg/mL; 4 PREFILLED GLASS SYRINGE in 1 CARTON (49401-0088-47) > 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42) |
07/01/2022 |
83.96 |
4282.17 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2022 |
58160097602 |
BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 1 Pack |
01/01/2022 |
9.55 |
200.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2022 |
58160097620 |
BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack |
01/01/2022 |
95.50 |
2005.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2022 |
58160081912 |
SHINGRIX 0.5mL Vial; Dosage form: Injection; 1 Pack |
01/01/2022 |
9.56 |
171.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2022 |
58160082311 |
SHINGRIX 0.5mL Vial; Dosage form: Injection; 10 Pack |
01/01/2022 |
95.59 |
1715.68 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2022 |
69656010330 |
ZEJULA 100 mg 30 CAPSULE in 1 BOTTLE |
01/01/2022 |
533.53 |
8155.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
01/22/2019 |
TESARO, INC |
None |
1 |
None |
6584.00 |
None |
2018 |
6584.00 |
None |
Note on Acquisition Fields
ACQUIRED_FROM_COMPANY: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself
ACQUISITION_PRICE: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself
WAC_YEAR_PRIOR_TO_ACQ: Zejula did not have a WAC one year prior to acquisition as it was not yet approved at that time |
| Rx0000123 |
Greenwich Biosciences |
03/31/2022 |
70127010010 |
Epidiolex 100mg/mL bottle |
01/10/2022 |
120.00 |
1540.00 |
03/01/2041 |
Single Source Drug |
None |
1 |
"Greenwich Biosciences, Inc. manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Greenwich also evaluates relevant market analogues to support a price increase. Greenwich engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product’s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted:
• Clinical value;
• HCP and Payer perceptions of a product’s clinical value;
• Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients;
• Research and Development costs associated with production of the drug;
• Historic WAC price;
• Greenwich's fiduciary responsibility to its shareholders." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 26, 2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Greenwich Biosciences, Inc. respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
The drug was not was acquired from another manufacturer within the last five years." |